PubMed CrossRef Jastreboff AM, Aronne LJ, Ahmad NN, et al
"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA , 2024
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
Total Billed once Monthly virtual visits Access to AI assistant Premium customer support Select Your Current Weight (lbs.) Disclaimer These results are derived from two separate patient cohorts: (1) individuals with initial visits on or after March 1, 2024 and baseline weights exceeding 175 lbs, who recorded an average weight loss of 9.75 lbs within the first month of enrollment
